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Abstract
In patients with end-stage renal disease (ESRD) treated with intermittent
haemodialysis, a limited number of antibiotics have been studied for their
suitability for parenteral administration after dialysis sessions only in a thrice-
weekly regimen. Temocillin is a β-lactam antibiotic with a long half-live and
enhanced activity against most Gram-negative bacteria, including extended-
spectrum β-lactamase-producers, thus making it an ideal candidate for use in
this setting. This study aimed to evaluate the reliability of thrice-weekly parenteral
temocillin in haemodialysis patients by characterising the pharmacokinetics of
total and free temocillin. Free and total temocillin concentrations were determined
with a validated HPLC method in 448 samples derived from 48 administration
cycles in 16 patients with ESRD treated with intermittent haemodialysis and
temocillin. Pharmacokinetics were non-linear partly due to saturation in protein
binding. Median clearance and half-life for the free ...
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a b s t r a c t
In patients with end-stage renal disease (ESRD) treated with intermittent haemodialysis, a limited
number of antibiotics have been studied for their suitability for parenteral administration after dialy-
sis sessions only in a thrice-weekly regimen. Temocillin is a -lactam antibiotic with a long half-live
and enhanced activity against most Gram-negative bacteria, including extended-spectrum-lactamase-
producers, thus making it an ideal candidate for use in this setting. This study aimed to evaluate the
reliability of thrice-weekly parenteral temocillin in haemodialysis patients by characterising the phar-
macokinetics of total and free temocillin. Free and total temocillin concentrations were determined with
a validated HPLC method in 448 samples derived from 48 administration cycles in 16 patients with ESRD
treated with intermittent haemodialysis and temocillin. Pharmacokinetics were non-linear partly due to
saturation in protein binding. Median clearance and half-life for the free drug during intradialysis and
interdialysis periodswere113mL/minvs. 26mL/min and3.6hvs. 24h, respectively,withdialysis extract-
ing approximately one-half of the residual concentration. The free temocillin concentration remained
>16mg/L (MIC90 threshold for most Enterobacteriaceae) during 48%, 67% and 71% of the dosing interval
for patients receiving 1g q24h, 2 g q48h and 3g q72h, respectively, suggesting appropriate exposure for
the two latter therapeutic schemes. Temocillin administered on dialysis days only in a dosing schedule of
2 g q48h and 3g q72h is appropriate for the treatment of serious and/or resistant Gram-negative infec-
tions in patients with ESRD undergoing intermittent haemodialysis. These doses are higher than those
previously recommended.
© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
1. Introduction
Patients with end-stage renal disease (ESRD) suffer signiﬁ-
cantly higher mortality than the general population, with values
48 times higher in the 20- to 44-year-old age group and 7 times
higher in the over 75 years age group [1]. Infections, especially
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septicaemia and pulmonary infections, are the second leading
cause of death in this population [2]. Historically, Gram-positive
infections were predominant in the haemodialysis population [3].
However, in the past few years a concerning rise in infections
caused by Gram-negative pathogens with increasing rates of drug
resistance in dialysis patients has fuelled a renewed interest in this
ﬁeld [3–5]. Parenteral antibiotics that permit thrice-weekly dosing
after each dialysis session are preferable because they can reduce
hospitalisation duration and costs as well as enhance quality of life
[1]. Whilst this common practice is supported by strong clinical
data for the treatment of Gram-positive infections with cefazolin
[6] or vancomycin [7], the antibioticsmost frequently administered
on dialysis days only for the treatment of Gram-negative infections
http://dx.doi.org/10.1016/j.ijantimicag.2015.09.005
0924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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Fig. 1. Study design. Temocillin was administered by intravenous bolus immediately after the haemodialysis (HD) session. This ﬁgure represents a typical end-stage renal
disease patient who undergoes HD thrice weekly, on Mondays, Wednesdays and Fridays. The study protocol foresaw the administration of 1, 2 or 3 g for a dosing interval of
24h, 48h or 72h, respectively. The 24-h interdialytic period is not represented in this ﬁgure.
have been shown to lead to inadequate exposure (ceftazidime) [8]
or unacceptable toxicity (aminoglycosides) [9].
In this setting, temocillin (an intravenous -lactam antibi-
otic with a long half-life [10]) constitutes a valuable candidate
as an anti-Gram-negative agent in settings where Pseudomonas
aeruginosa can be excluded [11]. Moreover, the remarkable sta-
bility of temocillin against most -lactamases, including AmpC,
extended-spectrum -lactamases and most carbapenemases,
fuelled a recent interest in this antibiotic as a carbapenem-sparing
agent [12]. For time-dependent antibiotics such as -lactams, the
probability of therapeutic success is related to the proportion of the
dosing interval during which their free concentration exceeds the
minimuminhibitory concentration (MIC)of theoffendingorganism
[13]. Therefore, their elimination rate will be a critical determi-
nant in their overall efﬁcacy and will dictate the frequency of their
administration.
Little is known, however, about temocillin pharmacokine-
tics/pharmacodynamics in ESRD patients as well as its dialysability
with contemporary high-ﬂux haemodialysers [11,14]. Its primar-
ily renal elimination (mainly by glomerular ﬁltration in unchanged
form) and long serumhalf-life comparedwith other-lactams [10]
render it suitable to be administered on haemodialysis days only.
This study aimed: (i) to characterise the pharmacokinetics and dia-
lytic clearance of temocillin in patients undergoing intermittent
haemodialysis; (ii) to determine the fraction of the dosage interval
duringwhich the free concentration exceeds theMICof target orga-
nisms if administered after each haemodialysis session; and (iii) to
propose and validate a dosing schedule on dialysis days only.
2. Methods
2.1. Study design and population
This prospective, single-centre (tertiary-care renal unit in
Belgium), open-label, non-randomised clinical study characterised
the pharmacokinetics of temocillin administered on dialysis days
only using a 1-, 2- or 3-day dosing interval. Patients undergo-
ing intermittent haemodialysis for ESRD for whom treatment with
temocillinwas indicated according to the attending physicianwere
eligible for the study. Exclusion criteria were: (i) age <18 years;
(ii) estimated life expectancy of <24h due to major co-morbid
conditions; (iii) pregnancy; (iv) IgE-mediated allergy to penicillins;
or (v)patientsnotgiving informedconsent. Theattendingphysician
determined the indication for temocillin use as well as its duration.
The dialysis schedule was according to clinical state of the art of
the study site and was not altered for the purpose of the study.
Urea clearance (Kt/V) was >1.2; blood ﬂow rates were set as high as
possible with a maximum of 400mL/min and pre-pump pressures
not lower than −250mmHg, unless there was a conﬁrmed disequi-
librium syndrome. Blood ﬂow rate, dialysate ﬂow rate, time and
other components of the dialysis prescription were determined
according to the clinical need by the attending physician. The dial-
ysers used were FX80 and FX10 (Fresenius Medical Care AG & Co.,
Bad Homburg, Germany).
2.2. Temocillin
Temocillin (Eumedica SA, Brussels, Belgium) was used through-
out the study period. Temocillin (1–3g) was dissolved in 25–75mL
ofwater for injection andwas administered intravenously over a 5-
min period directly after dialysis. In analogywithwhat is donewith
cefazolin [15], a ﬁxed temocillin dosing schedule of 1 g for a 24-h
(1-day) dosing interval, of 2 g for a 48-h (2-day) dosing interval and
of 3 g for a 72-h (3-day) dosing interval was used (Fig. 1).
2.3. Sample collection
Blood samples were drawn: (i) just before and at 0.5, 3, 6, 12,
20 (before dialysis) and 24h (at the end of dialysis) after temocillin
administration when patients were dialysed with a 1-day interval;
(ii) just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and
48h (at the end of dialysis) after temocillin administration when
patients were dialysed with a 2-day interval; or (iii) just before and
at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72h (at the end of
dialysis) after temocillin administration when patients were dial-
ysed with a 3-day interval. Additional blood samples were taken 1,
2, 3 and 4h after the start of dialysis. All samples were taken from
an arterial or venous catheter. Serum samples obtained by centrifu-
gation after blood clotting were frozen at −80 ◦C immediately after
sampling.
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2.4. Temocillin assays
Temocillin total serum concentrations were assayed by high-
performance liquid chromatography (HPLC) with ultraviolet
detection [16]. Free concentrations were determined by HPLC tan-
dem mass spectrometry after ultraﬁltration of serum samples
(2000× g, 25 ◦C, 20min) with an Amicon® Ultra-15 device (NMWL
30K; Merck-Millipore, Merck KGaA, Darmstadt, Germany) as vali-
dated previously [17]. In brief, reverse-phase chromatography was
performed using as mobile phase a gradient varying linearly from
100% 0.1% formic acid in water to 100% 0.1% formic acid in ace-
tonitrile with a 0.3mL/min ﬂow rate. Molecular ions were detected
in positive electrospray ionisation mode. In addition, the following
parameters were also recorded in all patients: time of drug admin-
istration; duration of dialysis and of the interdialytic interval; dry
body weight (determined at the end of dialysis); mean blood ﬂow;
ﬁlter used; total volumedialysed; total ultraﬁltration; urea and cre-
atinine concentration; patient age; and dialysis vintage (length of
time on dialysis).
2.5. Data analysis
Key pharmacokinetic (PK) parameters during the interdialytic
period [volume of distribution (Vd), clearance (CL), area under the
concentration–time curve (AUC) and elimination half-life (t1/2)]
were estimated using the non-compartmental ‘PK’ package (PK
version 1.3-2, CRAN) for R 3.0.2 using RStudio 0.98.501 (RStudio,
Boston, MA). During the dialysis period, the following parameters
were estimated:
Fe = (Cs,pre − Cs,post)/Cs,pre
where Fe is the fraction eliminated by dialysis and Cs,pre and Cs,post
are serum concentrations of temocillin at the beginning and end of
haemodialysis, respectively [18];
CLHD = [(Cs,pre − Cs,post) · Vd/AUCHD] − CL
where CLHD and AUCHD are the haemodialysis clearance and the
areaunder the concentration–timecurveduringhaemodialysis cal-
culated by the trapezoidal rule, respectively [19];
t1/2HD = ln(2)Vd/(CL − CLHD)
where t1/2 HD is the elimination half-life during haemodialysis [20];
and
URR = (BUNpre − BUNpost)/BUNpre
where URR is the urea reduction ratio and BUNpre and BUNpost are
the pre- and post-dialysis blood urea nitrogen (mg/dL) [19]. Data
were pooled by dose and were analysed independently, irrespec-
tive of sequence of doses.
The time during which free concentration (fT) stayed above a
given MIC was calculated by linear interpolation between mea-
sured values for the different dosing regimens. Target attainment
rate was calculated considering the fT ensuring a coverage of MIC
up to 8mg/L (temocillin breakpoint for systemic infections from
theBritish Society of Antimicrobial Chemotherapy (BSAC) [21]) and
16mg/L (presumed MIC for >90% of Enterobacteriaceae [22]).
2.6. Statistical analyses
Multiple comparisons were analysed by analysis of variance
(ANOVA). Overall, a P-value of ≤0.05 was considered statisti-
cally signiﬁcant. Since two tests were carried out independently,
Bonferroni-corrected signiﬁcance thresholds of P≤0.025 were
used to compensate for the increased type 1 error. Analyses were
conducted using R 3.0.2 with RStudio 0.98.501.
Table 1
Patient characteristics (n=16).
Characteristic Median Range
Age (years) 68.5 24–91
Follow-up (days) 5.5 2–9
Dosing cycles/subject 3 1–6
Dry body weight (kg) 73.1 41.5–104
Dialysis characteristics
Vintage (days) 453 4–2475
QBlood (mL/min) 328 154–396
QDialysate (mL/min) 500 500–500
Ultraﬁltration (mL) 1800 599–3200
Kt/V 1.51 0.87–1.88
Laboratory parameters
Albumin (g/dL) 3.3 2.1–4.4
AST (U/L) 19 12–40
BUNPre-dial (mg/dL) 107 10–169
CreatininePre-dial (mg/dL) 6.5 1.26–10.29
QBlood, blood ﬂow rate;QDialysate, dialysate ﬂow rate;Kt/V, urea clearance; AST, aspar-
tate aminotransferase; BUN, blood urea nitrogen; pre-dial, pre-dialysis.
3. Results
3.1. Patients and treatment
Sixteen patients were included in the study, including 14 males
and 2 females. Their underlying kidney diseases were diabetes
(n=5) and/or nephroangiosclerosis (n=7), chronic glomeru-
lonephritis (n=2), interstitial nephritis (n=1), polycystic kidney
disease (n=1), congenital reﬂux or hypoplasia (n=2) and acute
tubular necrosis (n=2). All patients were given temocillin as part
of regular medical therapy for suspected or documented Gram-
negative infection. Sepsis was observed in 44% of patients, and
infectiondiagnosis includedvascularnecrosis, pyelonephritis, peri-
tonitis, urinary tract infection, abscess, osteomyelitis, prostatitis,
pneumonia, endocarditis and cystitis. The causative pathogen iden-
tiﬁed in 11 (69%) of the patients was a Gram-negative organism
from the Enterobacteriaceae family: Escherichia coli (36%; n=4);
Klebsiella oxytoca (27%; n=3); Klebsiella cloacae (27%; n=3); and
Klebsiella pneumoniae (9%; n=1). Further patient characteristics are
summarised in Table 1. A total of 48 concentration–time curves
(from the administrationof temocillin until the endof the following
dialysis session) were included in this analysis, including 4 for 1 g
every 24h (q24h), 31 for 2 g every 48h (q48h) and 13 for 3 g every
72h (q72h) (the length of the interdialytic intervalwas determined
by thepatient’s clinical condition).All patientswerehaemodialysed
over 4h.
3.2. Pharmacokinetics
The mean serum concentration–time proﬁles of temocillin are
shown in Fig. 2. Both the actual total and free temocillin concen-
trations were measured because (i) only the free concentration is
anticipated to be pharmacologically active and (ii) there are huge
variations inproteinbinding inpatientswith advanced renal failure
[23], which makes reference to standard populations for extrap-
olating free concentrations from measured total concentrations
inadequate. Data analysis was carried out independently for the
interdialytic and intradialytic period. Key PKparameters during the
interdialytic period are summarised in Table 2both for the total and
free temocillin concentrations.
Exposure to total or free temocillin, determined by the area
under the concentration–curve up to the last measurable concen-
tration (excluding dialysis) (AUClast), was not proportional to the
dose (P≤0.025), suggesting non-linear pharmacokinetics. Compar-
ison of PK parameters for total and free drug showed that the
AUClast for the free concentration was 3-fold lower than for the
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Fig. 2. Serum concentration–time proﬁles of temocillin. Mean± standard deviation of total () and free (©) temocillin concentrations for the 1g (left panel), 2 g (middle
panel) and 3g (right panel) dosing regimens. Greyed areas correspond to the haemodialysis period (4h), with data shown in details in the inset.
Table 2
Pharmacokinetic (PK) parametersa for total and free temocillin concentrations for the three dosing regimens during the interdialytic period.
PK parameter Total concentrations Free concentrations
1g q24h 2g q48h 3g q72h 1g q24h 2g q48h 3g q72h
AUClast (mgh/L) 781 (83) 3352 (895) 5484 (1661) 276 (127) 1257 (651) 2677 (858)
AUCinf (mgh/L) 1749 (813) 5088 (1978) 7621 (2925) 713 (620) 1805 (988) 3122 (1024)
Vd (L) 17.7 (4.2) 15.6 (5.5) 20.7 (5.4) 60.6 (28.1) 43.9 (19.4) 33.3 (10.3)
Vd/Wt (L/kg) 0.26 (0.09) 0.23 (0.10) 0.31 (0.10) 0.8 (0.2) 0.6 (0.2) 0.5 (0.1)
CL (mL/min) 11.2 (5.1) 7.6 (2.9) 7.5 (3.1) 43 (39) 26 (16) 18 (6)
CL/Wt (mL/min/kg) 0.16 (0.07) 0.11 (0.06) 0.12 (0.06) 0.6 (0.4) 0.4 (0.2) 0.3 (0.1)
t1/2 (h) 22.5 (14.0) 26.0 (8.9) 35.8 (16.9) 23.6 (14.8) 24.1 (13.4) 22.8 (6.0)
q24h, every 24h; q48h, every 48h; q72h, every 72h; AUClast, area under the concentration–time curve up to the last measurable concentration (excluding dialysis); AUCinf,
area under the concentration–time curve from zero to inﬁnity (excluding dialysis); Vd, volume of distribution; Vd/Wt , volume of distribution per dry body weight; CL,
clearance; CL/Wt , clearance per dry body weight; t1/2, elimination half-life.
a Values are given as the mean (standard deviation).
total concentration for patients having received 1g or 2g, but
was only 2-fold lower for those having received 3g. The median
Vd across dosing regimens for free concentrations was 0.5 L/kg,
which is approximately two times higher than the corresponding
Vd for the total concentrations. Median free temocillin clearance
was 0.4mL/min/kg, which is approximately four times higher than
the total temocillin clearance. Note that free clearance was highest
in patients having received a 1g dose and appears to reduce with
increasing dosage. The elimination half-life (median, 24–26h) was
prolonged in ESRD patients and was similar across free and total
temocillin concentrations.
3.3. Haemodialysis efﬁcacy
Summaries of the haemodialysis efﬁcacy for temocillin are
shown in Table 3. Residual median temocillin concentrations
before starting dialysis were 13.4mg/L and 40mg/L for free and
total concentrations, respectively. They were markedly reduced
during haemodialysis across the three dosing regimens so as
to reach median concentrations of 6.5mg/L (free) and 16mg/L
(total). Median haemodialysis clearance for free temocillin was
113mL/min,which is approximately double the value found for the
total concentration. The interdialytic (4h) and intradialytic (>20h)
elimination half-lives were signiﬁcantly different (P≤0.025). The
estimated fraction eliminated by dialysis for the free concentra-
tion varied from 48% to 59%. The URR was ca. 70% across all dosing
groups.
3.4. Pharmacodynamics
The causative infectious pathogen was identiﬁed in 11 patients
(69%) and it belonged to the Enterobacteriaceae family. A recent
Table 3
Temocillin dialysis efﬁciency.a
Parameter 1 g q24h 2g q48h 3g q72h
URR (%) 63.3 (12.1) 72.4 (7.9) 71.1 (9.2)
Total concentrations
CLHD (mL/min) 67 (22) 39 (18) 77 (26)
t1/2 HD (h) 3.0 (0.5) 4.3 (1.5) 3.0 (1.1)
Fe (%) 58.9 (7.2) 48.6 (9.2) 58.5 (11.0)
Cs,pre (mg/L) 29 (11.7) 45 (20) 40 (19)
Cs,post (mg/L) 12 (4.4) 23 (10) 16 (8)
Free concentrations
CLHD (mL/min) 106 (9) 136 (83) 113 (61)
t1/2 HD (h) 4.1 (0.3) 3.6 (2.1) 3.2 (1.2)
Fe (%) 48.3 (4) 59 (15) 58 (12)
Cs,pre (mg/L) 3.4 (7.4) 13 (8.7) 15.1 (6.6)
Cs,post (mg/L) 7.1 (4.4) 4.7 (2.9) 6.5 (3.5)
q24h, every24h;q48h, every48h;q72h, every72h;URR, urea reduction ratio; CLHD,
dialysis clearance; t1/2 HD, elimination half-life during haemodialysis; Fe, fraction
eliminated by dialysis; Cs,pre and Cs,post, serum concentrations of temocillin at the
beginning and end of haemodialysis, respectively.
a Values are given as the mean (standard deviation).
Belgian survey reported MIC50/90 values of 8/16mg/L for temocillin
against these organisms [22]. Table 4 summarises the proportion of
the dosing interval during which the free temocillin concentration
remains above an MIC of 8mg/L (fT>MIC8) or 16mg/L (fT>MIC16)
taken as tentative susceptibility breakpoint values for temocillin
[21,24]. These values ranged from 78% to 90% and from 48% to 71%
when considering fT>MIC8 and fT>MIC16, respectively.
4. Discussion
This study is the ﬁrst to substantiate with robust PK data
that temocillin is a reliable option to treat serious Gram-negative
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Table 4
Percentages of the dosing interval that serum levels of temocillin are above clinically
relevant minimum inhibitory concentrations of pathogens.a
PK/PD criterionb 1 g q24h 2g q48h 3g q72h
%fT>8mg/L 78 (33) 88 (18) 89.5 (20)
% fT>16mg/L 48 (37) 67 (30) 71 (24)
PK/PD, pharmacokinetic/pharmacodynamic; q24h, every 24h; q48h, every 48h;
q72h, every 72h.
a Values are given as the mean (standard deviation).
b Percentage of the dosing interval that free serum temocillin concentrations are
>8mg/L and >16mg/L, respectively.
infections in ESRD patients when administered thrice weekly
on dialysis days only. Previous research on temocillin during
haemodialysis was limited to two studies conducted in the 1980s
with a small number (n=5–7) of patients and using older and less
efﬁcient low-ﬂux dialysers. The performance of these dialysers in
eliminating temocillin is inferior to that of contemporary high-
ﬂux dialysers, and modern pharmacokinetic/pharmacodynamic
(PK/PD) insights about parameters predicting the activity of -
lactams were not yet fully developed [11,25]. The applicability of
these outdated data to current practice is therefore questionable.
The pattern of Gram-negative organisms observed in this
study is similar to that typically seen in haemodialysis patients,
with E. coli and Klebsiella spp. being the most frequent orga-
nisms isolated [4]. The incidence of Gram-negative bacteraemia
in dialysis patients has increased during recent years and it
is associated with an unfavourable prognosis with a 3-month
mortality of 28.6% as well as non-dialysis access-related infec-
tion such as diabetic foot ulcer or urinary and intra-abdominal
infection [5]. There is a worrisome increase in antibiotic resis-
tance in Gram-negative organisms with resistance percentages
of >30% for ﬂuoroquinolones, trimethoprim/sulfamethoxazole and
conventional -lactams such amoxicillin/clavulanic acid, forcing
clinicians to resort to broad-spectrum drugs such as carbapenems
[3]. Temocillin is a strategically important alternative to carbapen-
ems in this context [12].
We observed a consistently high systemic exposure to
temocillin. The total volume of distribution is in agreement with
literature data [25] and does not appear to be signiﬁcantly affected
by renal insufﬁciency, as previously reported [11,14]. Free AUC
reaches 35–50% of total AUC depending on the dose, which is in
the same range as recent observations in severely ill patients hospi-
talised in intensive care units [24]. Both types of patients frequently
experience lower drug protein binding than healthy volunteers
[23,26], for whom temocillin free concentrations account for only
15% of total temocillin serum concentrations [10].
Wedemonstrate that temocillinpharmacokinetics aremarkedly
different during haemodialysis compared with the interdialytic
interval, with a clearance of 113mL/min vs. 26mL/min and a serum
half-life of 3.6h vs. 24h, respectively. This emphasises the need to
administer the drug after the dialysis session to accommodate for
intradialytic losses.
Temocillin has an extensive dialysability due to its low molec-
ular weight (<500Da) and its high degree of water solubility,
which is further enhanced by the low serum albumin levels fre-
quently observed in sickdialysis patients, as illustrated in this study
[23]. During the interdialytic period, temocillin exhibits complex,
non-linear pharmacokinetics,which can partly be attributed to sat-
urable protein binding [27]. Binding sites for temocillin have not
been identiﬁed, but it has been suggested that proteins other than
albumin could be involved especially at high temocillin concentra-
tions [28]. This couldbeof importance, particularly in inﬂammatory
situations where the serum concentration of albumin tends to
decrease while those of other proteins such as -1-acid glyco-
protein tend to increase. Non-linear pharmacokinetics may also
be partly explained by an increasing extrarenal elimination with
decreasing glomerular ﬁltration (likely biliary secretion), which
may become the main elimination pathway in patients with ESRD
[14]. Interestingly, the current data suggest a decrease in clear-
ance of free drug with increasing dose (only borderline statistically
signiﬁcant, probably due to the limited sample size), which is the
hallmark of a mixed-order elimination process. This explains the
subtherapeutic drug exposure observed with the lowest dose of
1 g per 24-h interval. It could correspond to a saturation of bil-
iary secretion at highantibiotic concentrationsbecause this process
requires the intervention of active transporters [27].
Regarding temocillin pharmacodynamics, its overall efﬁcacy is
best predicted, as for all -lactam antibiotics, by the time during
which the free concentration remains above the MIC of the offend-
ing bacteria (fT>MIC) [13]. There is, however, no clear consensus on
the fraction of the dosing interval during which the free concen-
tration has to remain above this MIC value. Animal models suggest
that a fT>MIC of 29–34% is required to achieve bacteriostasis against
most susceptible organismswhen using discontinuous administra-
tion [13].
Mathematicalmodels based onMonte Carlo simulations using a
cut-off fT>MIC of 40% suggest for temocillin a clinical PK/PD break-
point of 8–16mg/L [24], a value of the same order of magnitude
as the MIC90 for most Enterobacteriaceae [22]. This target was
reached for the 2g q48h and 3g q72h dosing regimens and only
partially reached for the 1g q24h regimen when considering an
MIC of 16mg/L. In order to maximise bacterial killing and thus
therapeutic efﬁcacy, values of fT>MIC as high as 50–100% have
also been proposed when dealing with more complicated infec-
tions in immunocompromised patients [22,29]. This goal could not
be achieved for patients receiving 1g q24h for whom temocillin
fT>MIC16 was <50%. Conversely, this value was obtained for the
majority of patients receiving 2g q48h or 3g q72h, with free con-
centrations remaining above an MIC of 8mg/L or 16mg/L during
ca. 90% and 70% of the dosing interval, respectively. However, still
higher exposure may be needed in order to prevent the emergence
of more resistant mutants, with trough values for free concentra-
tions as high as four times the MIC being recommended to avoid
selection of resistant subpopulations [30]. Based on these consid-
erations, it is obvious that the doses of temocillin recommended
in the Summary of Product Characteristics, being 0.5 g q24h and
1g q48h, will lead to subtherapeutic drug exposure in the majority
of patients [10], which may call for revision of these recommen-
dations. Noteworthy, temocillin was well tolerated in this ESRD
population.
This study has several limitations. First, we did not evalu-
ate whether rebound occurred in temocillin concentrations after
haemodialysis. If so, the half-life might be overestimated. Second,
the patients were not all at steady state, thus the potential for drug
accumulation with multiple dosing exists. However, haemodialy-
sis was highly efﬁcient at removing temocillin. Therefore, any drug
accumulation can be considered insigniﬁcant compared with other
sources of variability, and we estimated it to be less than one-half
of the accuracy of the analytical method (15%) used. Lastly, and in a
more global context, further studies are needed to more deﬁnitely
establish the optimal PK/PD target for-lactams in general, and for
temocillin in particular, in order to better deﬁne adequate dosing
regimens.
5. Conclusion
This study demonstrates that temocillin is a safe, effective,
strategically interesting, and easy-to-use therapeutic option in
ESRD patients undergoing intermittent haemodialysis provided
close attention is given to its proper dosing. The approach followed
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in this study could also be used to assess the reliability of other -
lactams for the treatment of ESRDpatients undergoing intermittent
haemodialysis. For the three dosing schedules studied, temocillin
trough levels before dialysis were relatively independent of the
dosing schedule, leaving room to explore the use of higher doses
in order to achieve a higher percentage of fT>MIC16, and decreasing
the risk of the emergence of bacterial resistance while patients are
undergoing treatment. In addition, the proposed regimen allows
for treatment of both inpatients and outpatients.
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